Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Intraoperative Electromyography can optimize pallidotomy for Parkinson’s disease and dystonias
Objective: The aim of this study is show our experience in use intraoperative electromyography during stereotactic pallidotomy for Parkinson’s disease and dystonia, to help care…Novel population-specific mutationsin PINK1 and Parkin genes from India
Objective: To look for novel and population-specific genes for PD in 50 Indian families with Parkinson's disease Background: Till date, 138 mutations in PINK1 and…Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease
Objective: To investigate the effectiveness of Levodopa carbidopa ascorbic acid solution (LCAS) in reducing the severity of bradykinesia and dyskinesia in advanced Parkinson’s disease (PD).…Dyskinesia-hyperpyrexia syndrome (DHS) after sudden interruption of deep brain stimulation and increase of oral dopaminergic therapy: A case report
Objective: To report the case of a PD patient treated with bilateral deep brain stimulation of subthalamic nucleus (STN-DBS) who developed DHS after the sudden…LRRK2 p.Leu119Pro and p.Leu488Pro in a family with neuropathologycally confirmed Parkinson´s disease without Lewy bodies
Objective: To describe the clinical features, genetic analysis and brain pathology of some members of a family affected by Parkinson´s disease. Background: Mutations of the…STN deep brain stimulation can directly suppress levodopa-induced dyskinesia in Parkinson’s disease
Objective: The study aims to evaluate the effect of bilateral STN-DBS on levodopa-induced peak-dose dyskinesia in patients with PD. Background: Dyskinesia is among the most…A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID
Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 40
- Next Page »